Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 4/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797144 | 0.89 | PRKD3 (0.45) | PRKD3PIM1GSK3AGSK3BIRAK1 | |
| SCHEMBL6800253 | 0.89 | PRKD3 (0.43) | PRKD3PIM1GSK3AGSK3BIRAK1 | |
| Hydrochloric Acid SCHEMBL7006179 | 0.88 | PRKD3 (0.44) | PRKD3PIM1GSK3AGSK3BIRAK1 | |
| Hydrochloric Acid SCHEMBL7014885 | 0.88 | PRKD3 (0.42) | PRKD3PIM1GSK3AGSK3BIRAK1 | |
| SCHEMBL6803225 | 0.87 | KMT2A (0.47) | PRKD3PIM1GSK3AGSK3BIRAK1 | |
| Hydrochloric Acid SCHEMBL7007292 | 0.86 | KMT2A (0.46) | PRKD3PIM1GSK3AGSK3BIRAK1 | |
| SCHEMBL6806741 | 0.86 | PIM1 (0.43) | PRKD3PIM1GSK3AGSK3BIRAK1 | |
| SCHEMBL6799833 | 0.85 | THRB (0.41) | KMT2AALDH1A1POLBNPSR1 | |
| SCHEMBL6803829 | 0.84 | PIM1 (0.47) | PRKD3PIM1GSK3AGSK3BIRAK1 | |
| SCHEMBL7014855 | 0.83 | TOP1 (0.42) | PRKD3PIM1GSK3AGSK3BIRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | claimed |
| US-6825199-B2 | 7-Substituted quinazolin-2,4-diones useful as antibacterial agents | WARNER-LAMBERT COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | disclosed |
| US-6331538-B1 | TREATMENT OF BACTERIAL INFECTION | WARNER-LAMBERT COMPANY | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | NQO2, TOP1, TOP2A | PRKD3 1822/4885PIM1 2808/4885GSK3A 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.